SUTOL BIO, Inc. — SEC Form D Filing

SUTOL BIO, Inc. filed an SEC Form D on November 10, 2026, reporting $474K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$474K
Round stage
Seed
Industry
Biotechnology
Website
https://sutolbio.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Poor adherence is a major challenge in chronic disease care, where daily pills frequently lead to missed doses and alternative long-acting injectables are painful, risk complications, and cannot be reversed once administered.

Solution

SUTOL Bio is developing a gram-scale monthly oral capsule that rests in the stomach to continuously deliver therapy for over 30 days from a single swallowed dose.

Why now

Decades of drug delivery engineering have converged with advanced biomaterials to enable high-capacity (gram-scale) gastric residence, bridging the gap between daily oral pills and invasive injectables.

Verdict

This round cleared because investors bought an inexpensive technological option on high-payload gastric delivery, not because the team de-risked the severe regulatory and gastrointestinal safety liabilities that stalled predecessor companies. Backers implicitly bet that achieving a "gram-scale" capacity jump would reignite biopharma licensing appetite for long-acting oral formulations. However, terminal upside remained strictly discounted by the tiny sub-$500k check size, which was only sufficient to generate preliminary benchtop validation rather than the expensive large-animal residency and retrievability data required to command institutional biotech valuations.

Source: SEC EDGAR Form D filing